bupivacaine hydrochloride

Bupivacaine hydrochloride (Vivacaine) is a long-acting, amide-type local anesthetic. Bupivacaine hydrochloride reversibly binds to specific sodium ion channels in the neuronal membrane, resulting in a decrease in the voltage-dependent membrane permeability to sodium ions and membrane stabilization; inhibition of depolarization and nerve impulse conduction; and a reversible loss of sensation.

UA8967 is a membrane-active anti-tumor agent. Cytotoxicity studies in six pancreatic cancer cell lines, one normal human pancreatic ductal epithelial line and two colon cancer cells showed the IC50s UA8967 ranged from 12–61 μM for exposure times of 72 h. There was also no selective inhibition of DNA, RNA or protein synthesis after exposure to UA8967. UA8967 is observed to affect the plasma membrane.

BupivacaineN-oxide hydrochloride is a metabolite of Bupivacaine. Bupivacaine acts as an NMDA receptor inhibitor and can block sodium, L-type calcium, and potassium channels. It effectively blocks SCN5A channels, with an IC50 of 69.5 μM. Bupivacaine is used in research related to chronic pain.

Levobupivacaine hydrochloride ((S)-(-)-Bupivacaine monohydrochloride) is a reversible neuronal sodium channel inhibitor and the pure S(-)-enantiomer of bupivacaine, used as a long-acting local anesthetic.

Bupivacaine hydrochloride monohydrate is a potent NMDA receptor inhibitor of sodium, L-calcium, and potassium channels.Bupivacaine hydrochloride monohydrate inhibits SCN5A channels and is commonly used in the study of chronic pain.

(R)-(+)-Bupivacaine hydrochloride is a voltage-gated sodium channel (sodium channel) inhibitor. It selectively blocks voltage-gated sodium ion channels on neuronal cell membranes, inhibiting the influx of sodium ions and thereby preventing the generation and transmission of nerve impulses, producing a local anesthetic effect. (R)-(+)-Bupivacaine hydrochloride can be used in acute pain research.

Lidocaine hydrochloride (Lignocaine hydrochloride) is a local anesthetic and cardiac depressant used as an antiarrhythmic agent. Its actions are more intense and its effects more prolonged than those of PROCAINE but its duration of action is shorter than that of BUPIVACAINE or PRILOCAINE.

Levobupivacaine is an amino-amide local anaesthetic drug belonging to the family of n-alkylsubstituted pipecoloxylidide. It is the S-enantiomer of bupivacaine. Levobupivacaine hydrochloride is commonly marketed by AstraZeneca under the trade name Chirocaine. Compared to bupivacaine, levobupivacaine is associated with less vasodilation and has a longer duration of action. It is approximately 13 per cent less potent (by molarity) than racemic bupivacaine.Levobupivacaine is indicated for local anaesthesia including infiltration, nerve block, ophthalmic, epidural and intrathecal anaesthesia in adults; and infiltration analgesia in children. Adverse drug reactions (ADRs) are rare when it is administered correctly. Most ADRs relate to administration technique (resulting in systemic exposure) or pharmacological effects of anesthesia, however allergic reactions can rarely occur.

Debutylbupivacaine is the intermediate of ropivacaine hydrochloride and bupivacaine.

Lidocaine-D10 hydrochloride is a deuterated compound of Lidocaine Hydrochloride. Lidocaine Hydrochloride (T1144) has a CAS number of 73-78-9. Lidocaine hydrochloride is a local anesthetic and cardiac depressant used as an antiarrhythmic agent. Its actions are more intense and its effects more prolonged than those of PROCAINE but its duration of action is shorter than that of BUPIVACAINE or PRILOCAINE.

Lidocaine-D6 hydrochloride is a deuterated compound of Lidocaine hydrochloride. Lidocaine hydrochloride has a CAS number of 73-78-9. Lidocaine hydrochloride (T1144) is a local anesthetic and cardiac depressant used as an antiarrhythmic agent. Its actions are more intense and its effects more prolonged than those of PROCAINE but its duration of action is shorter than that of BUPIVACAINE or PRILOCAINE.